Oppenheimer Asset Management Inc. Sells 46,381 Shares of Bristol Myers Squibb Company $BMY

Oppenheimer Asset Management Inc. reduced its position in shares of Bristol Myers Squibb Company (NYSE:BMY) by 8.7% in the fourth quarter, HoldingsChannel reports. The firm owned 485,157 shares of the biopharmaceutical company’s stock after selling 46,381 shares during the quarter. Oppenheimer Asset Management Inc.’s holdings in Bristol Myers Squibb were worth $26,169,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also made changes to their positions in the company. Darwin Wealth Management LLC bought a new stake in shares of Bristol Myers Squibb during the 2nd quarter valued at about $25,000. Physician Wealth Advisors Inc. lifted its position in shares of Bristol Myers Squibb by 73.5% during the 4th quarter. Physician Wealth Advisors Inc. now owns 477 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 202 shares in the last quarter. KERR FINANCIAL PLANNING Corp purchased a new position in shares of Bristol Myers Squibb during the 3rd quarter valued at about $35,000. JPL Wealth Management LLC purchased a new position in shares of Bristol Myers Squibb during the 3rd quarter valued at about $36,000. Finally, Beacon Financial Strategies CORP purchased a new position in shares of Bristol Myers Squibb during the 4th quarter valued at about $38,000. 76.41% of the stock is currently owned by institutional investors.

Bristol Myers Squibb News Roundup

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: BMY beat Q1 profit and revenue estimates, driven by growth‑portfolio drugs and Eliquis strength — a primary catalyst for the stock lift. Bristol Myers posts higher-than-expected quarterly profit
• Positive Sentiment: Company released Q1 results and slide deck, showing revenue of $11.49B and non‑GAAP EPS $1.58 — both above estimates — and reiterated FY2026 EPS guidance (6.05–6.35). Bristol Myers Squibb Reports First Quarter Financial Results for 2026
• Positive Sentiment: Management sounded confident on the Q1 call, highlighting cost‑cutting progress and growth‑portfolio commercialization that support near‑term outlook. Bristol-Myers Squibb Signals Confident Path After Q1 Call
• Positive Sentiment: Partnership expansion with Foundation Medicine on MTAP CDx strengthens BMY’s precision‑oncology positioning and could aid targeted pipeline development. Does BMS–Foundation Medicine’s MTAP CDx Partnership Expansion Change The Bull Case For Bristol-Myers Squibb (BMY)?
• Neutral Sentiment: Street consensus price target around $61.31 — roughly in line with the stock’s current level, implying limited near‑term upside from analyst targets alone. Bristol Myers Squibb Receives $61.31 Consensus PT from Analysts
• Neutral Sentiment: Bernstein maintains a Hold rating, reflecting a cautious view despite recent operational beats. Bernstein Sticks to Their Hold Rating for Bristol-Myers Squibb (BMY)
• Neutral Sentiment: Detailed Q1 slides and earnings transcript are available for investors wanting line‑item visibility into product performance and margin trends. Bristol-Myers Squibb Company 2026 Q1 – Results – Earnings Call Presentation
• Negative Sentiment: Analysts and industry commentary flag a major Eliquis patent cliff ahead — a material long‑term revenue risk that could pressure future sales as generics enter. Thinning revenues: inside the $14bn Eliquis patent cliff
• Negative Sentiment: While EPS guidance was reaffirmed, the midpoint of full‑year revenue guidance came in slightly below analysts’ expectations — a nuance that could limit upside if growth disappoints. Bristol-Myers Squibb (NYSE:BMY) Exceeds Q1 CY2026 Expectations

Analyst Ratings Changes

BMY has been the topic of a number of analyst reports. Wall Street Zen raised Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a research report on Sunday, April 19th. UBS Group reaffirmed a “buy” rating and set a $70.00 price objective on shares of Bristol Myers Squibb in a research report on Friday, March 6th. Barclays initiated coverage on Bristol Myers Squibb in a research report on Thursday, February 19th. They set an “overweight” rating and a $75.00 price objective on the stock. Leerink Partners boosted their price target on Bristol Myers Squibb from $54.00 to $60.00 and gave the stock an “outperform” rating in a report on Tuesday, January 13th. Finally, Scotiabank reissued a “sector perform” rating and issued a $60.00 price target (up from $53.00) on shares of Bristol Myers Squibb in a report on Friday, January 9th. Eight investment analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Bristol Myers Squibb currently has an average rating of “Hold” and a consensus target price of $61.31.

Bristol Myers Squibb Stock Performance

NYSE BMY opened at $60.75 on Friday. The company has a market cap of $124.04 billion, a P/E ratio of 17.61, a P/E/G ratio of 0.17 and a beta of 0.27. The company has a debt-to-equity ratio of 2.32, a quick ratio of 1.14 and a current ratio of 1.26. The business’s 50 day moving average price is $59.56 and its 200-day moving average price is $54.48. Bristol Myers Squibb Company has a fifty-two week low of $42.52 and a fifty-two week high of $62.89.

Bristol Myers Squibb (NYSE:BMY) last released its earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share for the quarter, beating the consensus estimate of $1.42 by $0.16. The firm had revenue of $11.49 billion for the quarter, compared to the consensus estimate of $10.93 billion. Bristol Myers Squibb had a return on equity of 69.65% and a net margin of 14.64%.The company’s revenue for the quarter was up 2.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.80 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Sell-side analysts predict that Bristol Myers Squibb Company will post 6.27 earnings per share for the current year.

Bristol Myers Squibb Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, May 1st. Shareholders of record on Thursday, April 2nd will be given a $0.63 dividend. This represents a $2.52 annualized dividend and a yield of 4.1%. The ex-dividend date of this dividend is Thursday, April 2nd. Bristol Myers Squibb’s dividend payout ratio is 73.04%.

Insider Buying and Selling

In other Bristol Myers Squibb news, EVP David V. Elkins sold 30,000 shares of the company’s stock in a transaction on Wednesday, April 1st. The stock was sold at an average price of $61.67, for a total value of $1,850,100.00. Following the transaction, the executive vice president owned 159,248 shares of the company’s stock, valued at $9,820,824.16. This represents a 15.85% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. 0.05% of the stock is owned by company insiders.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.